Targeting an IL-17/IL-36 pathogenic hub in hidradenitis suppurativa with a bispecific antibody.
Yonghu Sun, Zihao Mi, Yueqian Yu et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase I/II proof-of-concept clinical trial evaluated HB0043, a bispecific antibody targeting IL-17A and IL-36R, in patients with severe, tunnel-dominant Hurley Stage III hidradenitis suppurativa. The rationale came from multiomics findings implicating synergistic IL-17/IL-36γ inflammatory circuits in tunnels. At week 16, mean total abscess and inflammatory nodule count had fallen 82.13% from baseline; 100% achieved HiSCR50 and 80% achieved HiSCR75. Ultrasound showed tunnel regression, and no major short-term safety signals were reported.
Key findings
- At week 16, mean total abscess and inflammatory nodule count decreased 82.13% from baseline.
- HiSCR50 and HiSCR75 were achieved by 100% and 80% of patients, respectively.
- Ultrasound confirmed tunnel regression, with no major short-term safety signals reported.
- Longitudinal plasma proteomics showed reduced inflammation and restored metabolic homeostasis.
Why it matters
Tunnel-dominant HS can be difficult to treat, and the study links a tissue-level inflammatory mechanism to a targeted dual-blockade approach. The reported clinical and ultrasound changes suggest that addressing IL-17A and IL-36R together may merit further evaluation for advanced disease, while the early proof-of-concept findings do not establish comparative effectiveness or durable benefit.
What to keep in mind
The abstract describes a proof-of-concept trial and reports outcomes at week 16; it does not provide a comparator or sample size, limiting interpretation of efficacy and safety.